Can-Fite BioPharma Files 6-K, Incorporates Press Release
Ticker: CANF · Form: 6-K · Filed: May 6, 2024 · CIK: 1536196
| Field | Detail |
|---|---|
| Company | Can-Fite Biopharma LTD. (CANF) |
| Form Type | 6-K |
| Filed Date | May 6, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-K, registration-statement
TL;DR
Can-Fite BioPharma filed a 6-K on May 6, 2024, linking to their S-8 and F-3 filings.
AI Summary
On May 6, 2024, Can-Fite BioPharma Ltd. filed a Form 6-K, incorporating by reference a press release. This filing is related to their ongoing registration statements on Form S-8 and Form F-3, which are used for the issuance of securities. The company is based in Ramat Gan, Israel.
Why It Matters
This filing updates the company's disclosures with the SEC, which is important for investors to stay informed about the company's ongoing securities offerings and related filings.
Risk Assessment
Risk Level: low — This is a routine SEC filing (6-K) that primarily incorporates previous documents and does not appear to contain new material adverse information.
Key Numbers
- 001-36203 — SEC File Number (Identifies the company's SEC filing history)
Key Players & Entities
- Can-Fite BioPharma Ltd. (company) — Filer of the Form 6-K
- 0001213900-24-039894 (filing_id) — Accession Number for the filing
- May 6, 2024 (date) — Filing date and reporting period
- Ramat Gan, Israel (location) — Company's principal executive offices
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers that is required to be filed with the SEC to provide information that the issuer makes or is required to make public pursuant to the laws of the issuer's home country, or that it furnishes or is required to furnish to its security holders.
Which registration statements are being incorporated by reference?
The filing incorporates by reference Can-Fite BioPharma's Registration Statements on Form S-8 (File Nos. 333-227753, 333-271384, and 333-278525) and Form F-3 (File Nos. 333-195124, 333-236064, 333-249063, 333-262055, and 333-276000).
What is the company's primary business sector?
Can-Fite BioPharma Ltd. is in the Pharmaceutical Preparations industry, SIC code 2834.
When is the company's fiscal year end?
The company's fiscal year ends on December 31st.
Where are Can-Fite BioPharma's principal executive offices located?
The company's principal executive offices are located at 26 Ben Gurion Street, Ramat Gan, 5257346, Israel.
Filing Stats: 280 words · 1 min read · ~1 pages · Grade level 10.7 · Accepted 2024-05-06 07:11:47
Filing Documents
- ea0205283-6k_canfite.htm (6-K) — 10KB
- ea020528301ex99-1_canfite.htm (EX-99.1) — 12KB
- 0001213900-24-039894.txt ( ) — 24KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: May 6, 2024 By: /s/ Motti Farbstein Motti Farbstein Chief Executive Officer and Chief Financial Officer 2